# A Study of LY3375880 in Adults With Moderate-to-Severe Atopic Dermatitis

> **NCT03831191** · PHASE2 · TERMINATED · sponsor: **Eli Lilly and Company** · enrollment: 136 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** LY3375880
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03831191
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-02-12
- **Primary completion:** 2020-02-27
- **Final completion:** 2020-02-27
- **Target enrollment:** 136 (ACTUAL)
- **Why stopped:** The study was terminated for lack of efficacy after an interim analysis was performed
- **Last updated:** 2021-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03831191

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03831191, "A Study of LY3375880 in Adults With Moderate-to-Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03831191. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*